Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 7.18% |
| ALLIANCE FIB | AFOP | 5.89% |
| DAWSON GEOPH | DWSN | 4.86% |
| STEIN MART I | SMRT | 4.44% |
| MAXWELL TECH | MXWL | 3.33% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Rigel Pharmaceuticals’ ( RIGL - Snapshot Report ) fourth quarter 2012 loss of 30 cents per share was narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 36 cents. The narrower-than-expected loss was primarily due to the lower share count in the final quarter of 2012.
Rigel Pharma did not generate any revenues this quarter as well as in the prior year quarter. Research and development expenses came in at $19.8 million in the final quarter of 2012, flat year over year. General and administrative (G&A) expenses decreased 3.3% to $5.8 million in the final quarter of 2012.
Rigel Pharma suffered a loss of $1.32 per share in 2012, narrower than the 2011 loss of $1.36. The Zacks Consensus Estimate for 2012 hinted at a loss of $1.35 per share. Revenues decreased 52.6% to $2.3 million in 2012, short of the Zacks Consensus Estimate of $3 million.
All revenues in 2012 came from contracts. Contract revenue in 2012 primarily consisted of a $1 million upfront payment from AstraZeneca ( AZN - Analyst Report ) related to pipeline candidate R256 (moderate to severe chronic asthma). Contract revenue also included a payment of $0.8 million from Daiichi Sankyo pertaining to an oncology candidate.
We are encouraged by Rigel Pharma’s efforts to develop its pipeline. In Dec 2012, Rigel Pharma and partner AstraZeneca announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib for rheumatoid arthritis (RA).
The OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis)-4 study evaluated fostamatinib as a monotherapy in patients who had never been prescribed a disease-modifying anti-rheumatic drug (DMARD), or are intolerant or show insufficient response to DMARDs.
The pivotal phase III OSKIRA program is ongoing, results from which are expected in the second quarter of 2013. AstraZeneca plans to submit a marketing application in the US by year end.
Rigel Pharma currently carries a Zacks Rank #4 (Sell). Lannett Inc. ( LCI - Snapshot Report ) and QLT Inc. ( QLTI - Snapshot Report ) are well placed in the pharmaceutical space with a Zacks Rank #1 (Strong Buy).
Read the full reports :
Snapshot Report on RIGL
Analyst Report on AZN
Snapshot Report on QLTI
Snapshot Report on LCI